Syn2bio Spolka Akcyjna is a biotechnology company focused on developing innovative radiopharmaceuticals and pharmaceutical molecules. It specializes in the research, development, and commercialization of advanced diagnostic agents, particularly a cardio marker—an innovative radiopharmaceutical designed for heart disease diagnostics. The company also operates the Center for Research on New Molecules, dedicated to discovering novel pharmaceutical compounds, conducting further studies, achieving regulatory approvals, and introducing them as medical products to the market. Syn2bio Spolka Akcyjna targets the pharmaceutical and healthcare sectors, contributing to advancements in medical imaging and diagnostics. Its activities emphasize precision medicine solutions for cardiovascular conditions and beyond, positioning it as a key player in the biotechnology field. Headquartered in Warsaw, Poland, the company drives innovation in therapeutic and diagnostic technologies.